Trial Profile
TTP054, a Novel, Orally-Available Glucagon-Like Peptide-1 (GLP-1) in Subjects with Type 2 Diabetes Mellitus (T2DM)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Jul 2013
Price :
$35
*
At a glance
- Drugs TTP 054 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- 18 Jul 2013 New trial record
- 25 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.